Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease

Background and aims: To verify whether targeting defective mucosal T cell death underlies the sustained therapeutic benefit of infliximab in Crohn’s disease, we explored its in vivo proapoptotic effect after 10 weeks of treatment, and its in vitro killing activity on lamina propria T cells (LPT) and...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Di Sabatino, A, Ciccocioppo, R, Cinque, B, Millimaggi, D, Morera, R, Ricevuti, L, Cifone, M G, Corazza, G R
Format: Artigo
Idioma:Inglês
Publicat: Copyright 2004 by Gut 2004
Matèries:
Inflammatory Bowel Disease
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1773915/
https://ncbi.nlm.nih.gov/pubmed/14684579
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars